Massachusetts Eye and Ear Infirmary

Aldeyra Therapeutics, Inc.

The Schepens Eye Research Institute, Inc.

Dean Eliott

Stephen Gitu Machatha

Tomasz Pawel Stryjewski

Leo A Kim

Tomasz Stryjewski

Luk H Vandenberghe

Jason Comander

Pramod Sarpotdar

Joseph F Arboleda-Velasquez

Dhanesh Amarnani

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.

Ophthalmic formulations of methotrexate

Methods of delivering agents to structures within the eye are provided.

Methods of delivering an agent to the eye

The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.

Methotrexate treatment methods

The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.

RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition

The use of methotrexate, e.g., repeated dosing or sustained-release formulations of methotrexate, for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment.

Growing community of inventors

Carlsbad, CA, United States of America

Dean Eliott